American Journal of Cancer

, Volume 2, Issue 5, pp 305–311 | Cite as

Chronic Myeloid Leukemia

The Value of Tyrosine Kinase Inhibition
Leading Article


Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. The molecular hallmark of CML is the BCR-ABL gene rearrangement, which typically is generated by the Philadelphia (Ph) chromosome. The Ph chromosome abnormality arises as a result of a mutated stem cell acquiring a balanced reciprocal translocation involving chromosomes 9 and 22. The chimeric BCR-ABL gene encodes an oncoprotein, termed p210BCR-ABL protein, which has an enhanced and deregulated tyrosine kinase activity. It is generally regarded as the principal molecular cause of the initial indolent stage (chronic phase) of CML and further proof for this notion came from the remarkable activity of the Abl kinase inhibitor, imatinib mesylate (formerly STI 571). Imatinib mesylate targets the autophosphorylation of the Abl kinase specifically and is not only effective in the majority of patients, its also relatively free of major adverse effects. Current experience suggests hematological responses in over 95% of patients in the chronic phase of CML, with about 70% achieving a major cytogenic response. The drug is only able to achieve complete molecular responses in a minority of patients and so may not affect molecular cure. It is noteworthy that patients in the more advanced phases of CML, which involves additional clonal events, also respond to imatinib mesylate but have a high incidence of treatment resistance and relapse.



No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Fialkow PJ. Evidence for a multistep origin of chronic myeloid leukemia. Blood 1981; 58: 158–63PubMedGoogle Scholar
  2. 2.
    Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia [letter]. Science 1960; 132: 1497Google Scholar
  3. 3.
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–6PubMedCrossRefGoogle Scholar
  4. 4.
    Goldman JM, Apperley JF, Jones LM, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202–7PubMedCrossRefGoogle Scholar
  5. 5.
    Mughal TI, Yong A, Szydlo RM, et al. The probability of long-term leukaemia free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 2001; 115: 569–74PubMedCrossRefGoogle Scholar
  6. 6.
    Melo JV. The diversity of the BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–84PubMedGoogle Scholar
  7. 7.
    Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4–10PubMedCrossRefGoogle Scholar
  8. 8.
    Smith KM, Yacobi R, van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003; 12: 27–37PubMedCrossRefGoogle Scholar
  9. 9.
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 847–30CrossRefGoogle Scholar
  10. 10.
    Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–56PubMedGoogle Scholar
  11. 11.
    Anafi M, Gazit A, Zehavi A, et al. Tyrphostin-induced inhibition of p210 bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993; 82: 3524–9PubMedGoogle Scholar
  12. 12.
    Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR-ABL tyrosine kinase activity restores beta 1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998; 12: 1708–17PubMedCrossRefGoogle Scholar
  13. 13.
    Okabe M, Uehara Y, Miyagishima T, et al. Effect of Herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein p210 bcr/abl and preferential inhibition on Ph-positive leukemia cell growth. Blood 1992; 80: 1330–8PubMedGoogle Scholar
  14. 14.
    Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myeloid leukemia. J Clin Invest 2000; 105: 3–7PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman JM, Melo JV. Targeting the BCR-ABL kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1084–86PubMedCrossRefGoogle Scholar
  16. 16.
    Buchdunger E, Cioffi CL, Law N, et al. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45PubMedGoogle Scholar
  17. 17.
    Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 491–87CrossRefGoogle Scholar
  18. 18.
    Okuda K, Weisberg E, Gilliland DG, et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440–8PubMedCrossRefGoogle Scholar
  19. 19.
    Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938–42PubMedCrossRefGoogle Scholar
  20. 20.
    Demetri GD, von Mehren M, Blancke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002; 347: 472–80PubMedCrossRefGoogle Scholar
  21. 21.
    Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 2003; 348: 1201–14PubMedCrossRefGoogle Scholar
  22. 22.
    Goldman JM. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 2000; 355: 1031–2PubMedCrossRefGoogle Scholar
  23. 23.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7PubMedCrossRefGoogle Scholar
  24. 24.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–42PubMedCrossRefGoogle Scholar
  25. 25.
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–52PubMedCrossRefGoogle Scholar
  26. 26.
    Talpaz M, Silver RT, Druker B, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 2002; 99: 1928–37PubMedCrossRefGoogle Scholar
  27. 27.
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–9PubMedCrossRefGoogle Scholar
  28. 28.
    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003; 348: 994–1004PubMedCrossRefGoogle Scholar
  29. 29.
    Hughes TP, Kaeda J, Branford S, et al. On behalf of the IRIS study group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. New Engl J Med 2003; 349(15): 1423–32PubMedCrossRefGoogle Scholar
  30. 30.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80PubMedCrossRefGoogle Scholar
  31. 31.
    Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–9PubMedGoogle Scholar
  32. 32.
    Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemia cells through gene amplification. Blood 2000; 95: 1758–66PubMedGoogle Scholar
  33. 33.
    Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI5771 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498–505PubMedGoogle Scholar
  34. 34.
    Gambacorti-Passerini C, Barni R, le Courte P, et al. Role of alpha-1 acid glycoprotein in the in vivo resistance of human BCR-ABL leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641–50PubMedCrossRefGoogle Scholar
  35. 35.
    Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–25PubMedCrossRefGoogle Scholar
  36. 36.
    Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–8PubMedCrossRefGoogle Scholar
  37. 37.
    Shannon KM. Resistance in the land of molecular therapeutics. Cancer Cell 2002; 2: 99–102PubMedCrossRefGoogle Scholar
  38. 38.
    Von Bubnoff N, Schneller F, Peschel S, et al. BCR-ABL gene mutation in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487–91CrossRefGoogle Scholar
  39. 39.
    Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61(12): 1765–74PubMedCrossRefGoogle Scholar
  40. 40.
    Kantarjian HM, Talpaz M, O’Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myeloid leukemia. Blood 2003; 101: 473–5PubMedCrossRefGoogle Scholar
  41. 41.
    Cortes J, Giles F, O’Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after of interferon-α. Blood 2003; 102: 83–6PubMedCrossRefGoogle Scholar
  42. 42.
    Mughal TI, Goldman JM. Chronic myeloid leukaemia: STI571 magnifies the therapeutic dilemma. Eur J Cancer 2001; 37: 561–8PubMedCrossRefGoogle Scholar
  43. 43.
    Goldman JM, Druker B. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of Haematology, Faculty of MedicineImperial College London, Hammersmith HospitalLondonUK

Personalised recommendations